All In Biotech

Drug Trial Radar · NCT01294592

Comparative Efficacy of Dutasteride Plus Tamulosin With Lifestyle Advice Versus Watchful Waiting Plus Lifestyle Advice in the Management of Treatment naïve Men With Moderately Symptomatic Benign Prostatic Hyperplasia and Prostate Enlargement

Comparative Efficacy of DuodartTM Versus Watchful Waiting With Step-up Therapy to Tamsulosin in the Management of Treatment naïve Men With Symptomatic BPH

Last checked: Nov 20, 2026Latest source record: Aug 20, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 742 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

742

Actual

Start

Dec 22, 2010

Primary completion

Oct 17, 2013

Study completion Oct 17, 2013

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Feb 11, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Male only, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study FDC114615 is a two year, multi-centre, randomised, open-label trial to assess the efficacy of Dutasteride plus tamsulosin when compared to the standard practice of watchful waiting, with a defined escalation to tamsulosin in treatment naive men with symptomatic benign prostate hyperplasia (BPH). Once consented, each subject will undergo screening procedures to ensure the prostate volume and post void residual are within eligible range. If all entry criteria are met, subjects will be randomised (1:1) to receive Dutasteride plus tamsulosin with lifestyle advice or watchful waiting, with lifestyle advice, with a defined escalation to tamsulosin. Escalation will be initiated when no improvement from baseline is scored using the International Prostate Symptom Score (version 2) (IPSS) questionnaire. After randomisation, the subjects return to site at one month, then every 13 weeks until two years of treatment is complete or they are withdrawn. Key assessments, such as Adverse Events (AE's) and concomitant medication monitoring and completion of the quality of life questionnaires are performed at each visit and the data recorded.

Conditions

  • Prostatic Hyperplasia

Interventions

  • Dutasteride plus tamsulosinDrug

    Take 1 capsule daily

  • tamsulosinDrug

    Take 1 capsule daily when escalation criteria met

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in the Total International Prostate Symptom Score (IPSS) at Months 1, 3, 6, 9, 12, 15, 18, 21, and 24 Using the Last Observation Carried Forward (LOCF) ApproachTime frame: Baseline and Months 1, 3, 6, 9, 12, 15, 18, 21, and 24

Locations

80 sites in 8 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Aigrefeuille-sur-Maine, France

  • GSK Investigational Site

    Angers, France

  • GSK Investigational Site

    Angers, France

  • GSK Investigational Site

    Corsept, France

  • GSK Investigational Site

    La Montagne, France

  • GSK Investigational Site

    La Rochelle, France

  • GSK Investigational Site

    Laval, France

  • GSK Investigational Site

    Le Temple-de-Bretagne, France

  • GSK Investigational Site

    Mûrs-Erigné, France

  • GSK Investigational Site

    Nantes, France

  • GSK Investigational Site

    Nieul-sur-Mer, France

  • GSK Investigational Site

    Sautron, France

  • GSK Investigational Site

    Thouars, France

  • GSK Investigational Site

    Tiercé, France

  • GSK Investigational Site

    Vihiers, France

  • GSK Investigational Site

    Berlin, Germany

  • GSK Investigational Site

    Eisleben Lutherstadt, Germany

  • GSK Investigational Site

    Aichach, Bavaria, Germany

  • GSK Investigational Site

    Nuremberg, Bavaria, Germany

  • GSK Investigational Site

    Hagenow, Brandenburg, Germany

  • GSK Investigational Site

    Oranienburg, Brandenburg, Germany

  • GSK Investigational Site

    Strausberg, Brandenburg, Germany

  • GSK Investigational Site

    Marburg, Hesse, Germany

  • GSK Investigational Site

    Buchholz, Lower Saxony, Germany

  • GSK Investigational Site

    Essen, North Rhine-Westphalia, Germany

  • GSK Investigational Site

    Leipzig, Saxony, Germany

  • GSK Investigational Site

    Hettstedt, Saxony-Anhalt, Germany

  • GSK Investigational Site

    Kiel, Schleswig-Holstein, Germany

  • GSK Investigational Site

    Argos, Greece

  • GSK Investigational Site

    Athens, Greece

  • GSK Investigational Site

    Athens, Greece

  • GSK Investigational Site

    Athens, Greece

  • GSK Investigational Site

    Athens, Greece

  • GSK Investigational Site

    Larissa, Greece

  • GSK Investigational Site

    Pátrai, Greece

  • GSK Investigational Site

    Rhodes, Greece

  • GSK Investigational Site

    Thessaloniki, Greece

  • GSK Investigational Site

    Thessaloniki, Greece

  • GSK Investigational Site

    Vasto (CH), Abruzzo, Italy

  • GSK Investigational Site

    Foggia, Apulia, Italy

Showing 40 of 80 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.